menu
    • menu

    Company profile for Centus Biotherapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2015, Centus Biotherapeutics is a joint venture between AstraZeneca, a global pharmaceutical leader, and Fujifilm Kyowa Kirin Biologics (FKB), a Japanese biopharmaceutical company focused on biosimilar development. With the unique coupling of world class biologics expertise, global commercial infrastructure and deep biosimilar development experience, Centus Biotherapeutics is well positioned to win the trust of doct...
    Founded in 2015, Centus Biotherapeutics is a joint venture between AstraZeneca, a global pharmaceutical leader, and Fujifilm Kyowa Kirin Biologics (FKB), a Japanese biopharmaceutical company focused on biosimilar development. With the unique coupling of world class biologics expertise, global commercial infrastructure and deep biosimilar development experience, Centus Biotherapeutics is well positioned to win the trust of doctors and serve the needs of patients worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Centus Biotherapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.centusbiotherapeutics.com/home.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/centus-biotherapeutics-limited/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Genentech and Centus Notify Court of Settlement of Bevacizumab Litigation
    Genentech and Centus Notify Court of Settlement of Bevacizumab Litigation

    15 Apr 2021

    // BIGMOLECULEWATCH

    https://www.bigmoleculewatch.com/author/naomi-birbach/

    BIGMOLECULEWATCH
    15 Apr 2021
    Share Share
    Centus Biotherapeutics Equidacent (Bevacizumab)Receives Approval in Europe
    Centus Biotherapeutics Equidacent (Bevacizumab)Receives Approval in Europe

    12 Oct 2020

    // EMA

    https://www.ema.europa.eu/en/documents/overview/equidacent-epar-medicine-overview_en.pdf

    EMA
    12 Oct 2020
    Share Share
    Fujifilm Kyowa Kirin’s Avastin Biosimilar Approved in Europe
    Fujifilm Kyowa Kirin’s Avastin Biosimilar Approved in Europe

    30 Sep 2020

    // PHARMAJAPAN

    https://pj.jiho.jp/article/242917

    PHARMAJAPAN
    30 Sep 2020
    Share Share
    Centus Biotherapeutics Receives European Marketing Authorization for Equidacent®
    Centus Biotherapeutics Receives European Marketing Authorization for Equidacent®

    30 Sep 2020

    // PRESS RELEASE

    https://www.fujifilm.com/news/n200929_01.html

    PRESS RELEASE
    30 Sep 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search